TW202400572A - Erk的吡咯抑制劑之氘化類似物、其合成及其中間物 - Google Patents
Erk的吡咯抑制劑之氘化類似物、其合成及其中間物 Download PDFInfo
- Publication number
- TW202400572A TW202400572A TW112111234A TW112111234A TW202400572A TW 202400572 A TW202400572 A TW 202400572A TW 112111234 A TW112111234 A TW 112111234A TW 112111234 A TW112111234 A TW 112111234A TW 202400572 A TW202400572 A TW 202400572A
- Authority
- TW
- Taiwan
- Prior art keywords
- formula
- compound
- deuterium
- prepare
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323221P | 2022-03-24 | 2022-03-24 | |
| US63/323,221 | 2022-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202400572A true TW202400572A (zh) | 2024-01-01 |
Family
ID=88102044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112111234A TW202400572A (zh) | 2022-03-24 | 2023-03-24 | Erk的吡咯抑制劑之氘化類似物、其合成及其中間物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250026733A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4499623A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025509969A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119212985A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023238106A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245978A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315702A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011415A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400572A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023183905A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025250391A1 (en) * | 2024-05-28 | 2025-12-04 | Biomed Valley Discoveries, Inc. | Compositions and methods for solid forms of ulixertinib |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2897422T3 (es) * | 2004-05-14 | 2022-03-01 | Vertex Pharma | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| US9227969B2 (en) * | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| SG11201705924RA (en) * | 2015-01-30 | 2017-08-30 | Biomed Valley Discoveries Inc | CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb> |
-
2023
- 2023-03-24 WO PCT/US2023/064908 patent/WO2023183905A2/en not_active Ceased
- 2023-03-24 AU AU2023238106A patent/AU2023238106A1/en active Pending
- 2023-03-24 MX MX2024011415A patent/MX2024011415A/es unknown
- 2023-03-24 TW TW112111234A patent/TW202400572A/zh unknown
- 2023-03-24 CA CA3245978A patent/CA3245978A1/en active Pending
- 2023-03-24 JP JP2024556148A patent/JP2025509969A/ja active Pending
- 2023-03-24 IL IL315702A patent/IL315702A/en unknown
- 2023-03-24 CN CN202380038832.XA patent/CN119212985A/zh active Pending
- 2023-03-24 EP EP23775913.9A patent/EP4499623A4/en active Pending
-
2024
- 2024-09-23 US US18/893,686 patent/US20250026733A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4499623A4 (en) | 2026-08-05 |
| WO2023183905A3 (en) | 2023-10-26 |
| CA3245978A1 (en) | 2023-09-28 |
| AU2023238106A1 (en) | 2024-09-26 |
| EP4499623A2 (en) | 2025-02-05 |
| US20250026733A1 (en) | 2025-01-23 |
| JP2025509969A (ja) | 2025-04-11 |
| WO2023183905A2 (en) | 2023-09-28 |
| CN119212985A (zh) | 2024-12-27 |
| IL315702A (en) | 2024-11-01 |
| MX2024011415A (es) | 2024-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102725082B1 (ko) | Fxr 효능제의 고체 형태 | |
| JP2022071072A (ja) | (s)-7-(1-アクリロイルピペリジン-4-イル)-2-(4-フェノキシフェニル)-4,5,6,7-テトラ-ヒドロピラゾロ[1,5-a]ピリミジン-3-カルボキサミドの結晶形、その調製、及びその使用 | |
| TW201925182A (zh) | 磺醯胺化合物及其用途 | |
| KR20100050466A (ko) | 섬유증 저해제로서의 치환된 n-아릴 피리디논 | |
| AU2007310949A1 (en) | Substituted indoles | |
| US11534434B2 (en) | Xanomeline derivatives and methods for treating neurological disorders | |
| US7772248B2 (en) | Preparation and utility of substituted imidazopyridine compounds with hypnotic effects | |
| US20080132555A1 (en) | Preparation and utility of substituted phenyltetrazoles | |
| WO2007146124A2 (en) | Deuterated tadalafil derivatives | |
| EP2020849A2 (en) | Preparation and utility of substituted carboxylic acid compounds | |
| FR2941948A1 (fr) | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src | |
| US20250026733A1 (en) | Deuterated analogs of pyrole inhibitors of erk, synthesis thereof and intermediates thereto | |
| JP2004533448A (ja) | インスリン抵抗性症候群及び糖尿病の治療のためのアデノシン類似体 | |
| US20070287734A1 (en) | Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity | |
| HK40118078A (en) | Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto | |
| CN117279923B (zh) | 六元杂芳并脲环的衍生物及其应用 | |
| CN117700401A (zh) | 一种氘代物及其在医药上的应用 | |
| CN119053573A (zh) | 氘代咪唑克生及其使用方法 | |
| CN111630048B (zh) | 脒类和胍类衍生物、其制备方法及其在医药上的应用 | |
| JP7716147B2 (ja) | 置換されたイソインドリン-1,3-ジオン類pde4阻害剤及びその薬物応用 | |
| KR101547407B1 (ko) | 3-치환-6-(피리디닐메톡시)-피롤로피리딘 화합물 | |
| HK40113641A (en) | Solid forms of fxr agonists | |
| TW202517632A (zh) | 氘代1,3二氫-2h-吲哚-2-酮衍生物 | |
| CN118164979A (zh) | 氮杂吲哚类PI3Kδ抑制剂、其制备方法和应用 | |
| HK40023760B (en) | Sulfonamide compounds and use thereof |